San Diego-dependent Viking Therapeutics marked itself as a serious competitor from the weight loss drug industry in February right after revealing promising facts from a mid-phase demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when specified as a weekly injection As well as in March the company